An FDA-approved treatment that reverses or fully halts cognitive decline in Alzheimer's disease becomes availa

Question

Six frontier AI models put this at 10% by 23 Sept 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

10% — the median of 6 frontier models, resolving by 2036-09-23.

Answer

Gemini (Google): 8% — Halting or reversing neurodegeneration requires repairing lost synaptic architecture, which remains completely beyond the current drug pipeline. Any drug approved by 2035 must already be in Phase 2 trials today, yet zero active clinical candidates demonstrate full arrest or reversal. The historical Phase 2-to-FDA-approval rate in Alzheimer's is under 3%, and current anti-tau or multi-target agents only aim for marginal slowing. A decisive Phase 2 signal demonstrating sustained zero decline on CDR-SB by 2029 would be required to shift these odds upward.

Answer

Claude (Anthropic): 6% — No current pipeline drug shows reversal or full halt of decline, and FDA approval for such a claim by 2035 is unlikely. Approved anti-amyloid antibodies (lecanemab, donanemab) only modestly slow decline, not halt or reverse it, showing the ceiling of current mechanisms. Drug development timelines mean any truly disease-reversing therapy not already in late-phase trials by 2026 is very unlikely to reach FDA approval before 2035. A breakthrough combination therapy or novel mechanism (tau-clearance, neuroregeneration) showing dramatic phase 3 reversal data would be the game-changer to watch.

Answer

GPT (OpenAI): 18% — This hinges on whether late-stage trials can prove durable clinical reversal, not merely biomarker clearance, by 2035. FDA has approved lecanemab and donanemab for modest slowing; no approved program has demonstrated sustained cognitive restoration. A sponsor would need decisive Phase 3 results, FDA review, and launch by 2034–35, leaving little room for a failed pivotal trial. Odds rise sharply if a tau-, neuroinflammation-, or regenerative therapy shows replicated reversal on prespecified clinical endpoints by 2030.

Answer

Grok (xAI): 12% — Only a phase-3 asset already showing halt/reversal can finish trials, FDA review and launch by end-2034. Typical AD phase-3 plus FDA clock is 4–6 years, so candidates must be in or entering pivotal studies by ~2029. Historic AD phase-3 success is ~10 % and none have halted decline; current mAbs/tau agents produce only modest slowing. Clear reversal data from a regenerative or combo trial already under way would be the single event that lifts this probability.

Answer

DeepSeek (DeepSeek): 12% — A true Alzheimer's cure needs a mechanism that clears or prevents the damage, not just slows it. Lecanemab and donanemab only slow decline ~27-35% and carry ARIA risks, so they don't meet the bar. Amyloid-clearing has repeatedly failed to reverse symptoms; tau, inflammation, and synaptic repair remain unproven in humans. A single pivotal trial showing cognitive improvement, not just slowing, would be the first real signal; none exists yet.

Answer

Qwen (Alibaba): 7% — No candidate in Phase III shows reversal or full halt; the regulatory bar for that claim is far higher than what current pipelines demonstrate. Lecanemab and donanemab slow decline ~27-35% on CDR-SB but no Phase III candidate has shown zero decline or improvement; the gap from slowing to halting is… FDA would require a pivotal trial showing flat or improving trajectories on cognitive endpoints over 18+ months; even the most optimistic pipeline (e.g., combination… Base rate: zero disease-modifying therapies have achieved full halt or reversal in any neurodegenerative disease in 40 years of drug development; a breakthrough by 2035…

An FDA-approved treatment that reverses or fully halts cognitive decline in Alzheimer's disease becomes available before 2035.

What each one said

An FDA-approved treatment that reverses or fully halts cognitive decline in Alzheimer's disease becomes available before 2035.

A curative treatment for at least three of the top five deadliest cancers is approved by the FDA before October 2036.

A universal cure or vaccine effectively eliminating cancer mortality across most major types is approved by regulatory agencies before 2040.

The World Health Organization explicitly characterizes a Hantavirus outbreak as a pandemic in 2026.

An AI system is granted full regulatory approval to independently diagnose and prescribe treatment without doctor oversight by 2032.